-
1 month ago | 
lexology.com | Sarah Pennington |Paul Jorgensen |Kristin Wall
On March 6, 2025, British Columbia became the second province to announce the signing of a pharmacare agreement with Canada’s federal government. Manitoba was the first province to do so, on February 27, 2025 (our report here). British Columbia’s pharmacare agreementThe agreement follows from a September 2024 Memorandum of Understanding between the British Columbia and federal governments, stating an intention to negotiate a funding agreement (our report here).
-
1 month ago | 
lexology.com | Sarah Pennington |Paul Jorgensen |Kristin Wall
Canada has made wide-ranging amendments to the Food and Drug Regulations (FDR) and the Medical Devices Regulations (MDR). The amendments are intended to deliver on Health Canada’s modernization commitments, codify long-standing policies and practices, and implement regulatory agilities piloted during the COVID-19 pandemic. Some of the amendments are already in force, while others come into force later in 2025, 2026, and 2027.
-
1 month ago | 
lexology.com | Sarah Pennington |Paul Jorgensen |Kristin Wall
On February 27, 2025, the governments of Canada and of the Province of Manitoba announced the first-ever national pharmacare funding agreement. The two governments also announced a funding agreement under the National Strategy for Drugs for Rare Diseases. Pharmacare AgreementAs we reported, An Act respecting pharmacare (the Pharmacare Act) came into force on October 10, 2024.
-
Dec 11, 2024 | 
openlegalblogarchive.org | Sarah Pennington |Paul Jorgensen |Kristin Wall
Canada’s emerging national systems of pharmacare and public funding for drugs for rare diseases (DRDs) had key developments last week. On December 4, the Minister of Health (Minister) asked Canada’s Drug Agency-L’Agence des médicaments du Canada (CDA-AMC) for advice on a national formulary and a bulk purchasing strategy for pharmacare.
-
Nov 20, 2024 | 
corridor8.co.uk | Orla Foster |Sarah Pennington |Derek Horton
Sheila Gaffney’s feminist awakening happened while she was a student at Camberwell. In one sense, it was the most stimulating period of her life, an opportunity to spend hours in the studio absorbing knowledge from tutors who were masters of their craft, while also picking up habits and skills that would go on to shape her entire practice.
-
Sep 24, 2024 | 
witness.co.za | Sarah Pennington
“Count your blessings.” These words were spoken by an elderly man exactly at the moment I turned my TV on. It made me think, and think deeply. I reached a total of about 12 blessings in as many seconds. I stopped counting. We all complain so easily: “Would you believe the price of …” and, “Yet again no parking,” etc. Look around you and keep on counting. Sarah PenningtonHowick
-
Jun 4, 2024 | 
corridor8.co.uk | Sarah Pennington |Derek Horton |Sylvia Carpenter |Jessica Piette
Entering the gallery, I find a large tranquil space, suffused with the sounds of water and wildlife, unfamiliar language, the thrum of machinery and the banging of drums. Dimmed lights allow the films to glow from their positions on three walls, the polished white flooring softly reflecting the shifting colourways like peculiar aurora borealis reaching out to the audience seating before them.
-
Apr 16, 2024 | 
lexblog.com | Sarah Pennington |Paul Jorgensen |Kristin Wall
Canada’s federal 2024 budget has set aside $1.5 billion over five years to launch pharmacare, which will introduce national universal drug coverage to Canada. As we reported, on February 29, 2024, the federal government tabled Bill C-64, An Act respecting pharmacare (the Pharmacare Act). The Pharmacare Act outlines the first phase of a national universal drug coverage plan in Canada.
-
Apr 10, 2024 | 
lexblog.com | Sarah Pennington |Paul Jorgensen |Kristin Wall
The pan-Canadian Pharmaceutical Alliance (pCPA) has launched its Temporary Access Process (pTAP) to facilitate early market access to new drugs that were assessed under the time-limited reimbursement recommendation (TLR) pathway at the Canada Drug and Health Technology Agency (CADTH). The pCPA has published principles and conditions for the pTAP as well as information on its negotiation process and pricing.
-
Feb 25, 2024 | 
lexblog.com | Sarah Pennington |Paul Jorgensen |Kristin Wall
On February 23, 2024, Health Canada published a Notice advising that it was making its review process for generic drug submissions more transparent. Specifically, for generic drug submissions accepted into review on or after April 1, 2024, Health Canada will start disclosing: (i) the year and month that the submission was accepted for review; and (ii) the company sponsoring the generic drug.
